Kite Pharma, Inc. (NASDAQ:KITE) Files An 8-K Submission of Matters to a Vote of Security Holders

Kite Pharma, Inc. (NASDAQ:KITE) Files An 8-K Submission of Matters to a Vote of Security Holders

Story continues below

Item5.07.

Submission of Matters to a Vote of Security
Holders.

On June20, 2017, Kite Pharma, Inc. (the Company) held its Annual
Meeting of Stockholders at the Companys offices, located at 689
Fifth Avenue, 14th
Floor, New York, New York 10022 at 8:00 a.m. local time (the
Annual Meeting). At the Annual Meeting, the Companys stockholders
voted on five proposals, each of which is described in more
detail in the Companys definitive proxy statement on Schedule 14A
filed with the U.S. Securities and Exchange Commission on
April28, 2017. The following is a brief description of each
matter voted upon, and the certified results, including the
number of votes cast for and against each matter and, if
applicable, the number of abstentions and broker non-votes with
respect to each matter.

Proposal 1: Election of Directors

Each of the three nominees for ClassIII directors was elected to
serve on the Companys Board of Directors (the Board) until the
Annual Meeting of Stockholders in 2020 or until his respective
successor has been duly elected or qualified. The voting results
were as follows:


Director Name


Votes For

Votes Withheld

Broker Non-Votes


Mr.FranzB. Humer

35,363,841 1,091,692 9,798,105


Mr.JoshuaA. Kazam

34,737,961 1,717,572 9,798,105


Mr.StevenB. Ruchefsky

35,396,190 1,059,343 9,798,105

Proposal 2: Ratification of Selection of Independent
Registered Public Accounting Firm

The Companys stockholders ratified the selection by the Audit
Committee of the Board of ErnstYoung LLP as the Companys
independent registered public accounting firm for the year ending
December31, 2017. The voting results were as follows:


Votes For


Votes


Against


Abstentions


Broker Non-Votes

45,316,543 910,615 26,480

Proposal 3: Consideration of Stockholder Proposal Entitled
Elect Each Director Annually

The Companys stockholders approved the stockholder proposal
entitled Elect Each Director Annually. The voting results were as
follows:


Votes For


Votes


Against


Abstentions


Broker Non-Votes

29,423,200 6,964,275 68,058 9,798,105

Proposal 4: Advisory Vote on Executive Compensation

The Companys stockholders approved, on an advisory basis, the
compensation of the Companys named executive officers. The voting
results were as follows:


Votes For


Votes


Against


Abstentions


Broker Non-Votes

33,807,832 2,303,501 344,200 9,798,105

Proposal 5: Advisory Vote on the Frequency of Solicitation of
Advisory Stockholder Approval of Executive Compensation

The Companys stockholders approved, on an advisory basis, the
frequency of every one year as the frequency preferred by
stockholders for the solicitation of advisory stockholder
approval of the compensation paid to the Companys named executive
officers. The voting results were as follows:


Votes For


1 Year


Votes For


2 Years


Votes For


3 Years


Abstentions

34,888,458 233,685 911,278 422,112

Consistent with the preference of the Companys stockholders
indicated by the voting results with respect to this proposal,
the Company has decided to include an advisory vote on the
compensation of the Companys named executive officers every year
until the next required vote on the frequency of stockholder
votes on executive compensation.


About Kite Pharma, Inc. (NASDAQ:KITE)

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. It is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR-based therapy. It is conducting a Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with refractory diffuse large B cell lymphoma (DLBCL), including primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is also conducting a Phase II clinical trial (ZUMA-2) of KTE-C19 in patients with relapsed/refractory mantle cell lymphoma (MCL), a Phase I-II clinical trial (ZUMA-3) of KTE-C19 in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL), and a Phase I-II clinical trial (ZUMA-4) of KTE-C19 in pediatric patients with relapsed/refractory ALL.

An ad to help with our costs